Johnson & Johnson

NYSE:JNJ

Drug Manufacturers - General

Healthcare
$272.70 -1.96%

-$4.59 today

Market cap
$656.47B
Beta
0.26
P/E (TTM)
26.7
EPS (TTM)
$8.60
Dividend yield
2.28%
52W Low $149.04High $251.71

Volume 7.93M

Average 7.71M

JNJ Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Johnson & JohnsonNYSE: JNJ

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization remains negative

Q3 FY2026 depreciation & amortization was $0, compared with $1.78B a year earlier. Trailing-twelve-month depreciation & amortization was $5.97B. Over 3 fiscal years it compounded at +2.5% a year.

Context

  • Depreciation & amortization amounted to 8.0% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $1.49B.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$7.5B+2.2% YoY
LTMSep 2026
$5.97B-19.1% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+2.2%——
3-year CAGR+2.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
7.5B USD
Year-over-year change
+2.2%
4-year CAGR
+0.4%

Depreciation & Amortization vs competitors

How JNJ compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -19.1% is the 8th highest of 11, against a peer median of -7.0%.
  • Depreciation & amortization amounts to 6.0% of revenue for JNJ, versus a peer median of 9.9%.
JNJ Competitors
Depreciation & Amortization for JNJ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$6.72B USD+45.9%+14.3%10.1%
PFEPfizer Inc.LTM Jun 2026$6.58B USD-3.0%+9.2%10.3%
AZNAstraZeneca PLCLTM Sep 2026$6.41B USD+29.8%+3.0%10.3%
JNJJohnson & JohnsonLTM Sep 2026$5.97B USD-19.1%+2.5%6.0%
SNYSanofiLTM Jun 2026€5.88B EUR+22.9%+22.2%12.0%
ABBVAbbVie Inc.LTM Sep 2026$5.81B USD-29.7%-1.3%8.8%
NVSNovartis AGLTM Jun 2026$5.34B USD-11.0%-7.2%9.6%
AMGNAmgen Inc.LTM Jun 2026$4.67B USD-15.5%+14.8%12.2%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$3.18B USD-51.1%-26.9%6.5%
GILDGilead Sciences, Inc.LTM Jun 2026$2.76B USD-0.4%+9.5%9.1%
GSKGSK plcLTM Jun 2026£2.21B GBP-34.0%+2.5%6.7%
Peer median (excluding JNJ) —-7.0%+6.1%9.9%

Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.74B79.99B85.16B88.82B94.19B
Cost of Revenue23.4B24.6B26.55B27.47B30.26B
Gross Profit55.34B55.39B58.61B61.35B63.94B
Gross Margin70.3%69.3%68.8%69.1%67.9%
Research & Development14.28B14.14B15.09B17.23B14.67B
Selling, General & Admin20.12B20.25B20.11B21.97B23.68B
Operating Expenses34.4B34.38B35.2B39.2B38.34B
Depreciation & Amortization7.39B6.97B7.49B7.34B7.5B
EBITDA26.75B26.61B23.32B24.78B41.06B
EBITDA Margin34.0%33.3%27.4%27.9%43.6%
Operating Income20.94B21.01B23.41B22.15B25.6B
Operating Margin26.6%26.3%27.5%24.9%27.2%
Interest Income53M490M1.26B1.33B1.06B
Interest Expense183M276M772M755M971M
Other Income / Expenses(1.77B)(1.65B)(8.35B)(5.46B)6.99B
Income Before Tax19.18B19.36B15.06B16.69B32.58B
Pre-Tax Margin24.4%24.2%17.7%18.8%34.6%
Income Tax Expense1.38B2.99B1.74B2.62B5.78B
Net Income20.88B17.94B35.15B14.07B26.8B
Net Margin26.5%22.4%41.3%15.8%28.5%
EPS (Basic)7.936.8313.885.8411.03
EPS (Diluted)7.816.7313.725.7911.03
Weighted Avg Shares2.63B2.61B2.53B2.41B2.43B
Weighted Avg Shares (Diluted)2.67B2.66B2.56B2.43B2.43B

Johnson & Johnson

NYSE:JNJ

Intrinsic Alpha fair value

Locked

Current Price

$272.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.